Bertech Pharma Ltd. is a privately-held company focused on the development of colorectal cancer (CRC) diagnostics with proprietary biomarker technology, as well as the development of assessment assays and new treatments for CRC. We are committed to developing innovative products to assist physicians in both diagnosing CRC in its early stages and effectively treating it.
Through in-licensing, conducting additional development and out-licensing, we move technologies from leading research organizations through development and into the marketplace.
Latest News >
- March 11, 2020 — Bertech’s Pivotal Trial Validates Blood Test for Colorectal Cancer
- February 26, 2013 — Dr. David Dureck joins Bertech Pharma’s Scientific Board of Advisors
- September 06, 2012 — Dr. David Evans and Dr. Randall Johnston join Bertech Pharma’s Scientific Board of Advisors